This study is looking at patients with ovarian, fallopian tube, or primary peritoneal cancer who have been previously treated and now show signs of the cancer returning, or resistent to the previous treatment.  Patients are "randomized" on this study.  This means a computer tells the study team which treatment you will receive.  Neither the patient or the physician can choose the treatment assignment.  The purpose of Randomized trials is to equally study both treatment options using the same criteria in order to identify if one treatment may be superior to another treatment.  All patients will receive treatment with either the new drugs cediranib or olaparib, alone or combined, or the patient will receive the standard care treatment determined by the patient's physician.